Gerd Ritter

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Andrew M. Scott, G. Wiseman, Sydney Welt et al. · PubMed · 2003 · 441 citations

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Andrew M. Scott, Fook-Thean Lee, Niall C. Tebbutt et al. · Proceedings of the National Academy of Sciences · 2007 · 217 citations · Full text

Immunology, Dermatology, Immunotherapy +16

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily

Joan K. Heath, Sara J. White, Cameron N. Johnstone et al. · Proceedings of the National Academy of Sciences · 1997 · 190 citations · Full text

Murine A33 Mab, Immunology, Pathology +20

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

Achim A. Jungbluth, Elisabeth Stockert, Hongyi Huang et al. · Proceedings of the National Academy of Sciences · 2003 · 173 citations · Full text

Immunology, Pathology, Immunotherapy +18

The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies

Christoph Rader, Gerd Ritter, Sheila Nathan et al. · Journal of Biological Chemistry · 2000 · 128 citations · Full text

Therapeutic Human Antibodies, Immunocytochemical Technique, Immunology +20